E-SOLVE 2 Drug Patent Profile

Which patents cover E-solve 2, and what generic alternatives are available?

E-solve 2 is a drug marketed by Syosset and is included in one NDA.

The generic ingredient in E-SOLVE 2 is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for E-solve 2

A generic version of E-SOLVE 2 was approved as erythromycin by TORRENT on July 6^th, 2020.

Summary for E-SOLVE 2

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	108
Patent Applications:	4,046
DailyMed Link:	E-SOLVE 2 at DailyMed

US Patents and Regulatory Information for E-SOLVE 2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Syosset	E-SOLVE 2	erythromycin	LOTION;TOPICAL	062467-001	Jul 3, 1985		DISCN	No	No

E-SOLVE 2 (Drug): Market Dynamics and Financial Trajectory, Patent/Regulatory and Generic Entry Risks

Last updated: June 9, 2026

No market dynamics or financial trajectory can be produced for “E-SOLVE 2” as written, because “E-SOLVE 2” does not map to a single identifiable FDA-listed drug product, active ingredient, strength, dosage form, marketing company, or recognized global brand in the information available to me. Producing a quantified market or financial history would require an unambiguous drug identity.

What is “E-SOLVE 2” and what market data can be tied to it?

Answer: None, because the drug identity is not determinable from the name “E-SOLVE 2” alone.

Which active ingredient and dosage form does “E-SOLVE 2” correspond to?

No mapping is possible to a specific active ingredient, manufacturer, or dosage form.

Is “E-SOLVE 2” an FDA-approved brand, an investigational product, or a private-label product?

No determination is possible.

When did “E-SOLVE 2” launch and what does its FDA trajectory look like?

Answer: Not available, because a single definable FDA product cannot be identified.

What is the Orange Book status of “E-SOLVE 2”?

Not available.

What regulatory pathway was used (NDA, ANDA, 505(b)(2), BLA)?

Not available.

What patents protect “E-SOLVE 2” and what does that mean for competition?

Answer: Not available because the active ingredient and product are not identifiable.

How strong is the patent estate for “E-SOLVE 2”?

Not available.

Which companies are challenging “E-SOLVE 2” via Paragraph IV?

Not available.

What generic entry risks exist for “E-SOLVE 2”?

Answer: Not available.

What patent expirations or exclusivities drive generic timing?

Not available.

Does “E-SOLVE 2” have formulation, method-of-use, or manufacturing IP barriers?

Not available.

What are the commercial levers that typically drive revenue for branded drugs, and how do they apply here?

Answer: Cannot be applied without product identity.

Pricing, payer mix, channel strategy, and WAC vs net price

Not available.

Key prescriber or patient demand drivers

Not available.

Key Takeaways

No credible market or financial trajectory can be generated for “E-SOLVE 2” without a definitive identification of the underlying drug product (active ingredient, strength, dosage form, sponsor/marketing authorization holder, and territory).

FAQs

1. What active ingredient is “E-SOLVE 2” and how do I verify its regulatory listing?
2. Is “E-SOLVE 2” referenced in the FDA Orange Book or another exclusivity registry?
3. Are there known Paragraph IV filings or ANDA litigation tied to “E-SOLVE 2”?
4. How do formulation and method-of-use patents typically affect the launch timeline for similar products?
5. What data sources are used to build revenue and market forecasts for specialty vs primary-care drugs?

References (APA)

No sources were cited because no definitive drug identity could be established.